Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Chim Acta ; 400(1-2): 86-90, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19000909

ABSTRACT

INTRODUCTION: Preliminary studies report on significantly higher levels of the major cytoskeleton protein actin in CSF of patients with neurodegenerative conditions and that the dynamics of these levels obviously correlates with disease progression and clinical disability. One of the primary functions of actinfree Gc-Globulin is to bind and neutralize extracellular monomeric actin, released into the circulation by necrotic or ruptured cells, and thus ameliorating the clinical outcome in situations of severe organ damage. AIM AND METHODS: This is the first study to investigate actinfree Gc-Globulin and S100-B levels (as reliable marker of neurodegeneration) in paired CSF and serum samples of patients with multietiological CNS diseases. RESULTS: 42% of all patients with CNS disease displayed serum concentrations of actinfree Gc-Globulin above the established reference range. CSF concentrations of actinfree Gc-Globulin and S100-B were positively correlated with the severity of blood-brain barrier (BBB) dysfunction. Furthermore, patients with severe BBB dysfunction presented a higher percentage of intrathecal synthesis of actinfree Gc-Globulin compared to patients with mild to moderate dysfunction and to patients with normal BBB function. Representative longitudinal data from selected patients demonstrated an inverse behaviour of actinfree Gc-Globulin and S100-B CSF concentrations, suggesting a consumption of the actin scavenger capacity of Gc-Globulin in times of increased neuronal damage. This presumption was supported by the fact that those conditions associated with a severe neuronal damage, in particular CNS trauma, and highest S100-B concentrations simultaneously displayed lowest actinfree Gc-Globulin levels, and thus residual actin binding capacity of Gc-Globulin. CONCLUSION: In summary, our data propose a function of actinfree Gc-Globulin also in the clearance of actin filaments from CSF of patients with neuronal damage. However, active recruitment of hepatic derived actinfree Gc-Globulin to the site of CNS injury is not observed. Much more, BBB leakage enables extraneuronally synthesized actinfree Gc-Globulin to extent its scavenger capacity for actin also to the subarachnoidal space. Furthermore, intrathecal synthesis of actinfree Gc-Globulin seems to be increased in patients with severe neurodegeneration.


Subject(s)
Actins/metabolism , Blood-Brain Barrier/physiopathology , Nerve Growth Factors/blood , Nerve Growth Factors/cerebrospinal fluid , Neurodegenerative Diseases/metabolism , Neurodegenerative Diseases/physiopathology , S100 Proteins/blood , S100 Proteins/cerebrospinal fluid , Vitamin D-Binding Protein/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Brain Injuries/complications , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Neurodegenerative Diseases/pathology , Neurodegenerative Diseases/therapy , S100 Calcium Binding Protein beta Subunit , Time Factors , Treatment Outcome , Vitamin D-Binding Protein/biosynthesis , Vitamin D-Binding Protein/blood , Vitamin D-Binding Protein/cerebrospinal fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...